Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 14/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GRK5 | P34947 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10180992 | 0.81 | SLC6A1 (0.52) | LMNA | |
| SCHEMBL10180993 | 0.81 | SLC6A1 (0.52) | LMNA | |
| SCHEMBL884034 | 0.79 | S1PR5 (0.42) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL884032 | 0.79 | S1PR5 (0.42) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL25262763 | 0.78 | LTA4H (0.43) | PLGPLATLMNA | |
| SCHEMBL20139627 | 0.78 | CASP1 (0.33) | S1PR1 | |
| SCHEMBL11917621 | 0.77 | SMN1; SMN2 (0.51) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL1362081 | 0.77 | S1PR5 (0.41) | S1PR5S1PR1S1PR3S1PR4 | |
| Hydrochloric Acid SCHEMBL28065130 | 0.77 | SMN1; SMN2 (0.44) | PLGPLATLMNA | |
| SCHEMBL25024449 | 0.77 | S1PR5 (0.40) | S1PR5S1PR1S1PR3S1PR4GRK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | S1PR5 973/4885S1PR1 896/4885S1PR3 1217/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | S1PR5 973/4885S1PR1 896/4885S1PR3 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.